Recombinant lactic acid bacteria as promising vectors for mucosal vaccination

Abstract

Lactic acid bacteria (LAB), a diverse family of gram‐positive bacteria, has been proven effective in delivering varieties of therapeutic and prophylactic molecules such as antigens and cytokines. Featuring the properties of acid‐resistant, high uptake into Peyer's patches, and superior capacity for inducing secretory IgA antibodies, LAB have good potential to be used as vaccine vectors for mucosal vaccination. Mucosal immunization enables both mucosal and systemic immune responses, which are critical for resisting pathogens that invade the host through the mucosal surfaces. With the development of genetic engineering, LAB strains, primarily Lactococcus and Lactobacillus have been exploited to express a range of heterologous antigens. Numerous studies have demonstrated that LAB mucosal vaccines can stimulate all arms of the immune system to provide adequate protection against pathogen infections. Additionally, several LAB‐based human papillomavirus vaccines have entered the clinical trial studies, which suggest the great promise of LAB vaccines for new interventions in mucosal transport diseases. Herein, we will discuss the factors that influence the immunogenicity of LAB vaccines, including LAB strains, the location of antigens, and administration routes, and focus on the current strategies that have been reported for optimizing LAB vaccines.

Activation of Wnt/β-Catenin Signaling Involves 660 nm Laser Radiation on Epithelium and Modulates Lipid Metabolism

“…The Wnt/β-catenin pathway is involved in many biological processes, including modulating chronic inflammation [ 62 ], liver functions [ 63 ], regulating cell proliferation [ 64 ], genome stability [ 65 ], neurodegeneration [ 66 ], and cardiometabolic disorders [ 67 ]. Upregulating the Wnt/β-catenin pathway may be of great impact on breast vessel functions, including uremic vascular calcifications [ 68 ] and angiogenesis [ 69 , 70 , 71 ]. However, most vessel damage also induces downregulation of the Wnt/β-catenin pathway, and complementary Wnt sources can promote vascular development post damage [ 72 ].…”

A Novel Cuproptosis-Related Prognostic Model and the Hub Gene FDX1 Predict the Prognosis and Correlate with Immune Infiltration in Clear Cell Renal Cell Carcinoma

“…The CD274 was lower in the low FDX1 expression group, as were the CTLA4 , LAG3 , PDCD1 , PDCD1LG2 , and TIGIT , which were higher in the low FDX1 expression group. The results helped us better choose ICB for immune treatment or provided a theoretical basis for the development of new therapeutic strategies based on immune characteristics [ 61 , 62 ]. The immune response prediction results showed that low FDX1 expression had worse response.…”

Brain co‐delivery of first‐line chemotherapy drug and epigenetic bromodomain inhibitor for multidimensional enhanced synergistic glioblastoma therapy

“…As the pathogenic mechanisms of GBM are complex, [ 6 ] combinatorial therapy that targets multiple oncogenic molecular pathways has a better chance of avoiding the development of drug resistance associated with monotherapies. Recently, treatments that modulate immune‐regulation have attracted intensive attention, [ 7 ] strategies such as cancer vaccines, [ 8 ] immune checkpoint blockade immunotherapy, [ 9 ] and adoptive cell therapy (e.g., CAR‐T), [ 10 ] have shown encouraging clinical results in treating various types of cancers including GBM. Among them, blockade therapy using immune checkpoint inhibitors targeting the programmed death‐1 (PD‐1)/programmed death‐ligand 1 (PD‐L1) pathway, has become a first option for many cancers and has significantly changed the landscape of cancer therapy.…”